IIL to produce drug substance for Covaxin

Our Bureau Hyderabad | Updated on May 28, 2021

IIL is expected to produce the drug for about 10-15 million doses per month

Indian Immunologicals Ltd (IIL) is planning to start the production of drug substance for Bharat Biotech’s Covaxin, from June 15.

The first batch of the drug will be sent to Bharat Biotech by July, K Anand Kumar, Managing Director, IIL, said in a release issued here on Friday.

IIL is expected to produce the drug for about 10-15 million doses per month. Initially, it will produce for 2-3 million doses and it will be scaled up to 6-7 million per month later in the year, Kumar said.

The IIL is also working on Covid-19 vaccine and is expected to be launched by next year.

A technical collaboration agreement was inked between IIL and Bharat Biotech.

Under Atmanirbhar Bharat 3.0 Mission Covid Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous Covid Vaccines.

This is being implemented by the Department of Biotechnology. The IIL, Hyderabad has been sanctioned a grant of Rs 60 crore towards enhancing production capabilities.

Published on May 28, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.